Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hypogonadism

Interventions

DRUG: Androxal
DRUG: Placebo

Sponsor

Repros Therapeutics Inc.